

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|--|---|--|---|--|
| Infectious disease | | | | |
| HIV/AIDS | Lysine-specific histone demethylase 1 (KDM1A; LSD1) | <i>In vitro</i> studies suggest inhibiting LSD1 could prevent reactivation of latent HIV. In T cells with latent HIV infection, small hairpin RNA knockdown or small molecule inhibition of LSD1 prevented activation of HIV transcription compared with what was seen using shRNA or vehicle controls. Next steps could include developing more specific LSD1 inhibitors. | Patent and licensing status unavailable | Sakane, N. <i>et al. PLoS Pathog.</i> ; published online Aug. 18, 2011; doi:10.1371/journal.ppat.1002184 Contact: Melanie Ott, University of California, San Francisco, Calif. e-mail: mott@gladstone.ucsf.edu |
| <p>SciBX 4(37); doi:10.1038/scibx.2011.1044 Published online Sept. 22, 2011</p> | | | | |